The Ara Parseghian Medical Research Fund
The Ara Parseghian Medical Research Fund (APMRF) at Notre Dame is a non-profit organization dedicated to finding a treatment or cure for Niemann-Pick Type C (NPC) disease—a genetic, cholesterol storage disorder that primarily strikes children with death occurring before or during adolescence. The Parseghian Fund is named in honor of Ara Parseghian, the much beloved and well-known Notre Dame Football Coach, whose three youngest grandchildren were diagnosed with NPC in 1994. The Parseghian Fund supports NPC-focused medical research grants, which is the key to saving the lives of all those around the world afflicted with NPC disease.
This is who we Fight For
NPC disease is rare, but every child is worth Fighting For. There has been amazing progress in recent years that is positively impacting the lives of those afflicted by this horrible disease. The APMRF is currently funding 18 NPC research projects and we have seen many new and potentially life-saving therapies enter the clinic. Additionally, studying NPC is helping to unlock the mystery of many cholesterol related illnesses as well as viral infections including Ebola and coronavirus.
2021 Parseghian Classic
August 6-9, Pebble Beach, CA
The Parseghian Classic is a golf outing that benefits the Ara Parseghian Medical Research Fund's fight to find a cure for Niemann-Pick Type C disease.
About the Fund
The APMRF at Notre Dame is fighting for a cure for Niemann-Pick Type C—a rare and neglected disease that effects the lives of children.
Through gifts made to the Fund, we have provided millions of dollars in research funding around the globe that is leading towards a cure.
See our Impact
Current APMRF funding
The APMRF at Notre Dame is currently funding 18 high-impact & collaborative grants to help find a cure for NPC disease.
"There will be no cure without research and no research without funding."
- Ara Parseghian
NPC Community Updates
Mandos, LLC to acquire Adrabetadex from MallinckrodtMay 21, 2021
Survey on Preferences for Treatments for NPC DiseaseFebruary 2, 2021
Hear from Clinicians involved in the Adrabetadex Program – Webinar featuring Dr. Denny Porter and Dr. Elizabeth Berry-KravisJanuary 27, 2021
See All Stories